๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pharmacokinetics of midazolam during continuous infusion in critically ill neonates

โœ Scribed by E. Jacqz-Aigrain; P. Daoud; P. Burtin; S. Maherzi; F. Beaufils


Publisher
Springer
Year
1992
Tongue
English
Weight
388 KB
Volume
42
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

โœฆ Synopsis


Midazolam is a water soluble benzodiazepine, with a short elimination half-life in adults and children. An IV bolus (0.2 mg.kg-1) immediately followed by continuous infusion of 0.06 mg.kg-1.h-1 was administered to 15 critically ill neonates at a gestational age of 32.8 weeks, who required sedation for mechanical ventilation. Heart rate and blood pressure were closely monitored. Hypotension occurred in 4 patients after the bolus dose or during the continuous infusion. Three of them had also been given fentanyl. Individual pharmacokinetic parameters were calculated: plasma clearance was 3.9 ml.min-1, elimination half-life was 12.0 h. Because of its short half-life compared to diazepam, midazolam may be used during the neonatal period to achieve rapid, brief sedation. However, it should be administered cautiously to neonates, particularly in premature infants, or if fentanyl is also given.


๐Ÿ“œ SIMILAR VOLUMES


Pharmacokinetics of midazolam in critica
โœ E. Jacqz-Aigrain; C. Wood; I. Robieux ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› Springer ๐ŸŒ English โš– 224 KB

Midazolam is a water soluble benzodiazepine, with a short elimination half-life in adults and children. An IV bolus of midazolam 0.2 mg.kg-1 was administered to 10 critically ill neonates receiving intensive care who required sedation. The plasma clearance was 6.85 ml.min-1 and the elimination half-

The immunomodulatory effects of prolonge
โœ S. A. K. Helmy; R. J. Al-Attiyah ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 87 KB

Both propofol and midazolam are known to inhibit immune function. The aim of this study was to investigate cytokine production in critically ill surgical patients as early markers of immune response to prolonged infusion of propofol and midazolam. The study enrolled 40 elective patients who were to